NEO, US64049M2098

Needham raises target for NeoGenomics stock as Stone becomes CEO

Published on 10/07/2026 at 05:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Needham set USD 22.00, up from USD 19.00, on October 6, 2026. For NeoGenomics stock, preliminary revenue was USD 209.00 million.

NEO, US64049M2098, Illustration mit AI erstellt.

Needham raised its price target for NeoGenomics stock from USD 19.00 to USD 22.00 on October 6, 2026, while maintaining a Buy rating, according to Investing.com. The move followed NeoGenomics' succession plan, which names Warren Stone CEO effective January 4, 2027.

Stone takes over in January

NeoGenomics said on October 5, 2026, that Stone, its current President and Chief Operating Officer, will become CEO and join the board. Tony Zook will remain CEO through January 3, 2027, then become Executive Chairman, while Michael Kelly will become lead independent director.

The leadership change arrives alongside preliminary third-quarter revenue expected at USD 209.00 million and next-generation sequencing revenue growth of 28.00 percent year over year. The company said the third-quarter performance should lift the midpoint of its full-year revenue outlook.

Revenue growth supports the target

NeoGenomics generated USD 201.66 million of revenue in the second quarter of 2026, compared with USD 186.67 million in the first quarter. The finance data show net income attributable to common shareholders of USD 2.24 million in the second quarter, versus a USD 17.11 million loss in the first quarter.

Investing.com reported on October 6, 2026, that BTIG upgraded NeoGenomics to Buy from Neutral and set a USD 28.00 price target. BTIG cited a valuation gap, with the stock trading at three times 2027 consensus revenue compared with 11 times for specialty laboratory peers.

Valuation meets execution risk

The two analyst actions point to a split investor debate. Needham emphasized stronger near-term revenue, while BTIG focused on the possibility of valuation catching up with specialty laboratory peers.

The counterweight is execution during the management transition. NeoGenomics' preliminary third-quarter figures remain unaudited, and the company warned that final quarter-end adjustments could change the reported result or the full-year outlook.

NEO stays below its yearly high

NeoGenomics had a market capitalization of USD 424.1 million and a 52-week range of USD 7.07 to USD 20.15 as of October 6, 2026. The prior close at Lang & Schwarz was EUR 14.81 on October 5, 2026, while the October 6 data set showed a bid of EUR 14.84 and an ask of EUR 14.96.

The further course of trading is shown by the continuously updated real-time quote of NeoGenomics stock.